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fraction of the total neurons in 
the map, distribute their output, 
or ‘point’, to different regions of 
the cortical map. The strength 
of their pointing is determined 
by the external inputs, which 
then have control over the gain 
of the local circuits that form 
the cortical map. Thus in a 
situation where there are two 
competing inputs supplied by 
the feedforward circuits, the 
activity of one can be enhanced 
at the cost of the other by the 
pointer neuron system. 
Conclusions
A surprising, but consistent 
pattern across all areas of 
neocortex examined, is that 
the most of the thousands 
of synapses formed on the 
dendritic tree of any neuron 
come from its neighbouring 
excitatory neurons located in 
the same cortical area. Very few 
synapses are contributed by long 
distance connections, whether 
they arise from neurons in 
subcortical nuclei (principally the 
thalamus) or other cortical areas. 
Thus, the local circuit is the 
heart of cortical computation. 
While limitations on connectivity 
and power, and the necessity of 
robustness and reliability, have 
no doubt propelled the evolution 
of this kind of neocortical 
architecture, the consequences 
of this architecture have been 
difficult to study experimentally, 
particularly so in the case of 
the physiological interactions 
of local versus long distance 
projections. Thus, although we 
have developed very powerful 
tools, such as molecular and 
optical methods, for observing 
fine details of the structure and 
function of neocortical circuits, 
the challenge of understanding 
how these circuits actually 
work and what they actually do 
has not diminished. Here we 
have offered an interpretation 
of the neocortical architecture 
and have used simple models 
to illustrate some possible 
mechanisms by which the local 
recurrent circuits behave and 
interact with the long distance 
‘feedforward’ or ‘feedback’ 
projections. Already these rather 
simple circuits provide a rich set 
of behaviours that are consistent 
with known computations of the 
neocortex. 
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“We all labour against our own 
cure; for death is the cure of all 
diseases.” So reflected Sir Thomas 
Browne, the great 17th-century 
physician and aphorist. In our 
society today we labour even 
harder; death is no longer seen as 
a valid option, more as an affront 
to medical science. Well within 
living memory cancer treatment 
was a hit-and-miss affair. The way 
George Bernard Shaw saw it, if 
the patient died it was put down 
to ‘natural causes’, while if he 
lived, the doctor took the credit. 
The available treatments were 
surgery, radiation and a little later, 
chemotherapy of an unsparing 
kind, likened by David Nathan to 
carpet-bombing — destruction, 
that is, of the entire terrain in the 
hope of knocking down the target 
before the patient. But now such 
butchery is being edged out, 
as Nathan’s title implies, by the 
rigours of science, and the skills of 
the ‘physician scientists’, virtuosos 
of the genome and the proteome, 
no less than of the stethoscope 
and scalpel. Drugs of a new kind 
are directed not just at malignant 
cells, but at those of the particular 
malignancy, and they have induced 
recoveries unimaginable a decade 
or two ago.
David Nathan is an eminent 
doctor, researcher and teacher, 
whose academic progeny populate 
medical faculties around the 
world. He speaks, we may take 
it, with authority, and this book 
now reveals him to be a writer 
of enviable lucidity and style. He 
has built his narrative round the 
fortunes of three patients with 
Magazine
R501whose cases he was associated. 
All had been brought low by 
different cancers, each one 
rare and of uncommon ferocity; 
two were pulled back from the 
brink and cured (defined by a 
remission of five-years or a lifetime, 
whichever might be the longer), 
and one died after enduring a 
succession of heroic therapies. 
The narrative thread is cleverly 
interspersed with dissertations 
on the science of cancer, on 
discoveries old and new and 
on how they came about. It is 
enlivened by character sketches of 
the protagonists (names that will be 
familiar to scientific readers), and 
spiced with colourful anecdotes. 
These digressions both educate 
and heighten the suspense: the 
patient waits on the operating 
table or in the scanner cavity, while 
Nathan dilates on the mechanism 
of malignant transformation and 
the logic of what is to happen next.
We live, Nathan instructs us, 
in stirring times. Curiosity-driven 
research has proved its worth 
again, and has shown up once 
more the futility of steering science 
from above. The Nixon cancer 
programme (resting on the premise 
that cancer could be ‘engineered’, 
just like the moon landings) 
produced little but inferior science 
at huge cost. For science, as 
Peter Medawar affirmed, is the 
art of the soluble, and it was the 
discoveries of molecular genetics, 
of cell biology and of nucleic 
acid and protein structure, and 
innovations in the physics of 
imaging (on which Nathan lays 
great stress) that cleared the way. 
One lesson to emerge is that 
cancers come in endless varieties. 
They may result from a jammed 
accelerator — an unregulated 
cell division signal — or from 
a faulty brake — a defective 
tumour suppressor gene. ‘Smart’ 
drugs to combat cancers of the 
first category are designed to 
inhibit expression of the mutated 
gene (oncogene) or the action 
of its product. Many aberrant 
genes result from chromosomal 
translocations — a fragment 
detached from one chromosome 
and integrated into another, so 
as to produce fusion proteins. A 
well- studied form of leukaemia 
ensues when chromosomes 9 and 22 exchange parts of their DNA. 
In its unaccustomed location the 
piece of chromosome 9, which 
harbours a tyrosine kinase gene, 
gives rise to a fusion protein. 
This chimera is hyperactive, and 
so generates an unremitting cell 
proliferation signal. 
It was such a mutation that 
brought one of Nathan’s three 
cases, a nineteen-month old 
boy in extremis, to the Boston 
Children’s Hospital. A different 
reciprocal translocation smote 
another of the patients with one of 
the most refractory of all cancers, 
a gastrointestinal stromal tumour. 
The remedy, the elusive magic 
bullet, a highly specific inhibitor 
of the aberrant enzyme, was 
indeed at hand, and its effect 
appeared miraculous. But cancer 
cells mutate like bacteria; the 
susceptible ones yield to the drug, 
but the few in which a mutation 
evades the action of the inhibitor 
eventually grow, and the hunt for a 
new inhibitor begins again. In the 
end, the oncologist in the case ran 
out of options and the patient died.
An especially felicitous feature 
of Nathan’s discourse is the 
way in which he uncovers the 
path of discovery from a stray 
observation in a laboratory years 
earlier, through the apprehension 
in some unrelated context of 
its significance, to its deeper 
examination, and the sudden 
perception of its bearing on cancer; 
then follow all the vicissitudes of 
drug design, the long, hazardous 
and hideously expensive clinical 
trials, and once in a while a 
victorious outcome. Some of the 
great advances have sprung, 
on the other hand, from what 
appeared quite trifling insights. 
One such, and perhaps the most 
important, was the recognition that 
to avert recurrence of a cancer 
through successive mutations 
there must be no half-measures 
in pressing the initial assault. 
Shakespeare’s Claudius put the 
matter succinctly: “…diseases 
desperate grown/ By desperate 
applications must be reliev’d,/ Or 
not at all.” The principle is that a 
cancer should be attacked with all 
the available drugs at the outset, 
for using a single drug invites 
recurrence. This was initially a 
contentious proposition, which drew Nathan into a remarkable and 
painful encounter.
Sidney Farber was the doyen 
of paediatric oncologists. A man 
of legendary charm, charisma 
and gravitas, he had created, 
through the force of his personality 
and unflagging persistence, the 
Children’s Cancer Research 
Foundation, the famous Jimmy 
Fund, linked to Harvard, and he 
had dedicated his life to the search 
for the ‘magic bullet’ that would 
eliminate childhood leukaemia. 
He found indeed, some fifty years 
ago, a pair of related drugs that 
appeared specific and effective, 
aminopterin and methotrexate 
(both still in use). But the cure 
proved a delusion, for the children 
all relapsed within a year. Farber 
did not repine but continued on his 
course, convinced that more drugs, 
given singly and sequentially, 
would prevail. Other drugs, albeit 
of lower specificity, were available, 
yet Farber would not hear of 
multi-drug regimes, which he 
believed would inflict indefensible 
suffering on the children. When 
the virtues of multi-drug treatment 
became clear Farber remained 
unmoved. David Nathan was by 
then chief of Haematology at the 
Children’s Hospital. Convinced 
by the evidence against Farber’s 
methods, he had no choice but to 
confront the old autocrat and make 
his position clear. An apprehensive 
Nathan was not even permitted to 
make his case, for Farber quickly 
whipped himself into a paroxysm of 
anger. When Nathan indicated that, 
in the face of such intransigence, 
he would in future refer no more 
children with leukaemia to the 
Jimmy Fund Clinic, Farber 
responded by bringing out a match 
and snapping it between finger and 
thumb. Throwing the pieces on the 
desk, he uttered the words, “I’ll 
break you like that.” Sidney Farber 
died late one night at his desk soon 
after this episode, not before, in 
a poignant coda to a remarkable 
career, anointing as his successor 
one of the most vocal proponents 
of multi-drug therapy.
Nathan’s book bubbles with 
optimism. The three patients, his 
exemplars, are intelligent and 
resolute; they are blessed with 
brilliant doctors (for isn’t this 
after all Harvard?), access to the 
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Oceanic islands frequently support 
endemic faunal radiations that are 
highly vulnerable to introduced 
predators [1]. This vulnerability 
is epitomized by the rapid 
extinction in the wild of all but five 
of 61 described Society Islands 
partulid tree snails [2], following 
the deliberate introduction of an 
alien biological control agent: the 
carnivorous snail Euglandina rosea 
[3]. Tahiti’s tree snail populations 
have been almost completely 
extirpated and three of the island’s 
eight endemic Partula species 
are officially extinct, a fourth 
persisting only in captivity [2]. We 
report a molecular phylogenetic 
estimate of Tahitian Partula 
mitochondrial lineage survival 
calibrated with a 1970 reference 
museum collection that pre-dates 
the predator’s 1974 introduction 
to the island [4]. Although severe 
winnowing of lineage diversity has 
occurred, none of the five primary 
Tahitian Partula clades present in 
the museum samples is extinct. 
Targeted conservation measures, 
especially of montane refuge 
populations, may yet preserve 
a representative sub-sample of 
Tahiti’s endemic tree snail genetic 
diversity in the wild.
In 1970, one of us (J.B.B.) 
collected extensive samples of all 
nominal Tahitian Partula species, 
apart from the single mountain 
endemic P. cytherea, from 28 
valleys. A representative sub-
sample of Burch’s specimens, 
chosen to reflect Crampton’s shell 
phenotype-designated taxa [5] and 
their distribution among Tahitian 
valleys in 1970, was genotyped 
for a mitochondrial (mt) marker, 
as were samples of extant captive 
and recently acquired (2004–2006) 
relict wild populations (see 
Supplemental data available on-
line with this issue for experimental 
procedures). Figure 1 graphically 
represents a genealogical 
assessment of historical 1970 
Tahitian Partula populations 
relative to contemporary captive 
and wild survivors. Five primary mt 
clades were recovered. Each clade 
contains haplotypes from  
multiple nominal species, a 
prevailing condition in partulid 
mt gene trees [6], attributed to 
extensive hybridization [7] and/or 
ancestral polymorphisms [6]. 
Although severe and extensive 
topological pruning has occurred, 
lineage extinction has not 
proceeded to completion in any 
of these primary clades, including 
those containing the extinct 
nominal taxa P. filosa (Clade 2) and 
P. producta (Clade 3).
Clades 1–4 contain lineages 
from valley and montane 
populations and the gene tree 
topology highlights their strikingly 
different fates (Figure 1). Valley 
populations were rapidly extirpated 
following predator contact [8] and 
sampled extant valley lineages 
are restricted to captive lines of 
nominal P. affinis (Clade 1) and 
P. nodosa (Clade 3). In contrast, 
montane populations of these 
four mt clades persisted after 
initial predator contact [4]. This 
persistence is evident in the Mount 
Marau population used to seed 
captive lineages of P. otaheitana 
in 1995. Genotyping of six wild 
Marau snails biopsied in 2005 
recovered two of the four captive 
Marau mt lineages established a 
decade earlier (Clades 2, 3) and 
a larger sampling effort might 
have retrieved the remainder. Our 
molecular data reveal the potential 
conservation value of montane 
nominal P. otaheitana populations, 
for example, captive Mount 
Marau snails alone collectively 
encompass almost half of Tahitian 
Partula mt treespace (Figure 1). 
It is not clear whether nuclear 
gene trees would corroborate this 
inferred mt diversity; the montane 
populations have not been 
studied and allozyme datasets 
can be incongruent with both 
morphological and mt inferences most advanced equipment and 
to drugs, sometimes wheedled 
out of a pharmaceutical company 
before they have been licensed. 
They are supported by parents or 
spouses who scan the internet for 
names of the top specialists, and 
refuse to contemplate surrender. 
The treatment these patients 
receive is at the very cutting-edge 
of modern practice, sometimes 
experimental. One cannot help 
then but wonder how they might 
have fared had they lived in the 
rural south or a tenement in the 
East Bronx and without all the 
moral resources. Nathan does not 
allude directly to that question, 
but he is uncompromising in his 
observations on the many evils 
of the U.S. health system. He is 
scathing about the Federal Drug 
Authority, the once proud and 
admired FDA, now emasculated 
by the sinister hirelings of the 
current regime. He points, by way 
of illustration, to its persistent 
opposition to the introduction 
of an effective cervical cancer 
vaccine, on the grounds that it 
might be seen to condone sexual 
promiscuity.
In writing this engrossing 
book, Nathan has done us all a 
service. It will inform and educate 
doctors and others in the caring 
professions and those of us with 
a foot in the biomedical sciences, 
just as much as laymen. For them 
he provides an excellent glossary 
and for the rest of us a scholarly 
apparatus with 236 references. 
Those with a yearning for 
immortality (not through their work, 
but, as Woody Allen put it, by not 
dying) will derive some hope from 
the text. The rest of us may content 
ourselves with the reflection that 
we shall soon after all be able 
to survive everything except 
death. Recall also the paean to 
his cancer by the great biologist, 
J.B.S. Haldane (‘I wish I had the 
tongues of Homer/ To sing of rectal 
carcinoma …’), and its conclusion: 
“My final word before I’m 
done
Is, cancer can be rather 
fun” — well, at least for the reader.
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